|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17.02.26 - 22:24
|
USANA Health Sciences Reports Fourth Quarter and Full Year 2025 Results and Provides Fiscal Year 2026 Outlook (Business Wire)
|
|
|
SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended January 3, 2026.
Key Financial and Operating Results
Q4 2025
Q4 2024
FY 2025
FY 2024
Net sales
$226.2
$213.6
$925.3
$854.5
Net (loss) earnings*
$-1.8
$4.5
$10.8
$42.0
Diluted EPS
$-0.10
$0.23
$0.58
$2.19
Adjusted diluted EPS(1)
$0.60
$0.64
$1.93
$2.59
Adjusted EBITDA(2)
$27.3
$25.5
$101.3
$110.3
USANA Active Customers
387,000
454,000
387,000
454,000
Hiya Active Monthly Subscribers
181,700
N/A
181,700
N/A
*Pretax earnings for Q4 2025 totaled $4.0 million with income tax expense of $5.8 million. The adjustment to income taxes during the period, largely as a result of one-time impairment and cost realignment charges, is about $3.1 million greater than what would have been expected using the previously expected 65% tax rate.
Net sales, Net (loss) earnings and Adjusted EBITDA fig...
|
|
|
|
|
|
|
12.01.26 - 12:18
|
USANA Health Sciences Provides Preliminary Fiscal Year 2025 Net Sales and Issues Initial Fiscal Year 2026 Net Sales Outlook (Business Wire)
|
|
|
SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) today announced preliminary fiscal year 2025 net sales and initial net sales guidance for fiscal year 2026 ahead of its presentation at the 28th Annual ICR Conference. At the conference, Doug Hekking, CFO, and Walter Noot, COO, will discuss USANA's strategy, including the Company's initial fiscal year 2026 sales outlook.
Preliminary Fiscal Year 2025 Net Sales Results
The Company currently anticipates fiscal year 2025 consolidated net sales of approximately $925 million, ahead of its most recently issued guidance of approximately $920 million.
Initial Fiscal Year 2026 Net Sales Outlook
The Company is issuing its initial net sales outlook for fiscal year 2026 in the range of $925 million to $1.0 billion.
The Company's initial fiscal 2026 net sales outlook reflects:
Net sales from USANA, our core nutritional business, of $720 to $765 million (compared to preliminary net sales for fiscal 2025 of approximately $777 million);
Net sales...
|
|
|
08.01.26 - 15:06
|
Kevin Guest Returns to USANA Health Sciences as CEO (Business Wire)
|
|
|
SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) announced today a leadership transition as part of the Company's ongoing commitment to accelerating growth and enhancing shareholder value. Kevin Guest is returning to lead the Company as Chief Executive Officer, effective immediately. Mr. Guest, who has spent more than three decades at the Company, including eight years as CEO and the last three years as Executive Chairman, has agreed to again serve as USANA's CEO and will continue serving as Chairman. Mr. Guest succeeds Jim Brown, who has stepped down from his position of CEO and President.
“We thank Jim for his contributions and his leadership over the past 19 years and in his role as CEO over the past 3 years,” said Gilbert Fuller, lead independent director of the Board. “As USANA enters its next phase, the Board believes this transition will position the Company to accelerate strategic priorities that meaningfully contribute to long-term growth opportunities.”
“Kevi...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
